Clinical Trials Logo

Clinical Trial Summary

Regenerative surgery is an emerging multidisciplinary field actually based on derived adipose tissue. Autologous fat grafting was first described by Neuber in 1893 and since then it has developed over the next century. The initial goal of fat grafting was to treat volume losses created by disease or trauma. Further studies done by Zuk et al. in 2001 showed that lipoaspirate contains multipotent adipose stem cells (ADSCs) like in the bone marrow, thereby expanding opportunities in multiple fields. ADSCs have emerged as a key element of regenerative medicine surgery due to their ability to differentiate into a variety of different cell lineages. Moreover, their capacity of paracrine secretion of a broad selection of cytokines, chemokines, and growth factors make them highly clinically attractive. More specific, of particular interest are the anti-apoptotic, anti-inflammatory, proangiogenic, immunomodulatory, and anti-scarring effects that have been demonstrated for ADSCs, which effects on wound healing, soft-tissue restoration and scar remodelling. Nanofat firstly introduced by Tonnard in 2013, is an ultra-purified adipose tissue-derived product that is devoid of mature adipocytes but rich in ADSCs and with regenerative properties.


Clinical Trial Description

Lichen sclerosus is a chronic, inflammatory, mucocutaneous disorder of genital and extragenital skin. It was first described by Hallopeau in 1881. In 1976, the International Society for the Study of Vulvovaginal Disease concluded that the terminology LS should be adopted for men and women. Both sexes are affected, but it is 6 to 10 times more prevalent in women than in men. LS can occur at any age, but the incidence increases with age. The aetiology of LS remains unknown thought infectious, autoimmune, and chronic irritation was investigated for the develop of LS. The autoimmune pathogenesis seems most likely. An increased incidence of autoantibodies to the extracellular matrix protein and autoantibodies to BP180 antigen in LS are reported .Other potential markers include CD4+ T-cells clones, which are found in overabundance in LS patients's tissue. and possibly promote fibroblast cell proliferation. Risk factor to progression of LS was occlusion and exposure of urine. The susceptible epithelium may play a central role in the pathogenesis of LS. The skin may have an isotraumatopic response, to urine, feces, and other non-specific liquid irritants in occluded spaces and may play an important role in the etiology of LS in both men and women. The Köbner phenomenon describes the occurrence of disease- specific lesions on normal appearing skin after trauma and it is described in LS. Mechanical factors like friction due to tight clothing, occlusion, surgical trauma, radiotherapy and scars are thought to play an important role in triggering and maintaining LS . Some patients with lichen sclerosus do not have any symptoms, while most patients experience intense itching, discomfort and/or erosions/ulcers. LS is a debilitating disease, causing itch, pain, dysuria and restriction of micturition, dyspareunia, and significant sexual dysfunction in women and men. Vulvar itching, bleeding, or pain, pain during sex, skin bruising and tearing , blisters, easy bleeding from minor rubbing of the skin, trouble urinating or pain with urination, painful erections (in men). Lichen sclerosus typically has a remitting relapsing course that is complicated by permanent scarring of the affected areas. Biopsy is worthwhile both to confirm the diagnosis and to exclude malignant change. It has been suggested that the expression of selected cellular markers (such as p53, survivin, telomerase, Ki-67, and cyclin D1) can help distinguish between indolent LS and LS with true malignant potential. Topical and systemic treatments have been addressed but with few results. Surgery represent the solution for genital and urethral involvement. Depending on extension of genital and urethral involvement, surgical repair can range from a minimally invasive treatment to a more extensive reconstruction but still today surgery represents an open debate. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05464290
Study type Interventional
Source University of Roma La Sapienza
Contact
Status Recruiting
Phase N/A
Start date July 25, 2022
Completion date January 25, 2023

See also
  Status Clinical Trial Phase
Completed NCT03572348 - VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures. N/A
Completed NCT02321670 - Scandinavian Urethroplasty Study N/A
Recruiting NCT05519566 - The Accuracy of Pulsed Fluoroscopy Retrograde Urethrogram Vs the Traditional Retrograde Urethrogram In Diagnosing Urethral Stricture N/A
Recruiting NCT04071925 - 9000 URETHRA STUDY: a Study About Urethroplasty for Urethral Stricture Disease
Terminated NCT02551783 - Dorsal vs. Ventral Buccal Graft Dorsal vs. Ventral Buccal Graft N/A
Active, not recruiting NCT03270384 - Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease N/A
Not yet recruiting NCT03258658 - Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures Phase 1
Completed NCT03973619 - Urethral Stricture: A Comparison Between Jugal or Labial Graft Urethroplasty N/A
Recruiting NCT04965025 - Multi-stage Urethroplasty With Augmentation Using a Dorsal Graft Inlay Technique Comparing Graft Use in First or Second Stage N/A
Withdrawn NCT03851952 - Re-Establishing Flow Via Drug Coated Balloon for the Treatment of Urethral Stricture Disease - Registry Study N/A
Recruiting NCT04161365 - Feasibility and Therapeutic Potential of Free Fat Grafts in the Treatment of Urethral Strictures N/A
Completed NCT02948842 - Clostridium Histolyticum Collagenase Injection for Urethral Disease Phase 2
Not yet recruiting NCT06384066 - Mobile Health Application to Improve Patient Satisfaction After Urethroplasty N/A
Completed NCT03859024 - Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty Phase 4
Active, not recruiting NCT03499964 - ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease N/A
Terminated NCT02634619 - A Study of Dorsal Versus Ventral Buccal Mucosa Graft Onlay for Bulbar Urethroplasty N/A
Not yet recruiting NCT00918528 - Effect of Mitomycin C on Urethral Stricture Recurrence After Internal Urethrotomy Phase 1/Phase 2
Not yet recruiting NCT06064968 - Effectiveness of Intermittent Bladder Catheterization (IBC) in Reducing Recurrence of Urethral Stricture N/A
Completed NCT05078788 - Holmium Laser Uretherotomy in Combination With Intralesional Steroids in Bulbar Uretheral Stricture N/A
Enrolling by invitation NCT03205670 - Tissue-engineered Construct Based on Buccal Mucosa Cells and Matrix From Collagen and Polylactoglycolide Fibers Early Phase 1